Coronavirus company news summary – WHO suspends hydroxychloroquine and lopinavir/ritonavir arms of the RECOVERY trial – UK signs Covid-19 vaccine supply deal with GSK and Sanofi

Allie Nawrat 6 July 2020 (Last Updated July 6th, 2020 09:07)

6 July 2020 

The European Commission has provided conditional marketing authorisation for Gilead Sciences' Veklury (remdesivir) to treat Covid-19. Gilead noted that the approval comes after a rolling review of supporting data that started in April this year. The authorisation enables use of Veklury in adults and adolescents aged 12 years and above with Covid-19-related pneumonia who need supplemental oxygen.

The World Health Organization (WHO) has decided to discontinue hydroxychloroquine and lopinavir/ritonavir arms in its Solidarity Trial of potential treatments for hospitalised Covid-19 patients. The decision is based on the trial’s International Steering Committee's review of data that showed  these drugs offer little or no reduction in the mortality compared to standard of care.

The UK is set to sign a $624m Covid-19 vaccine supply deal with GlaxoSmithKline (GSK) and Sanofi, reported the Sunday Times. The agreement, which would be for 60 million doses of the vaccine candidate, follows a similar supply deal signed by the government with AstraZeneca for 100 million doses of the Oxford Covid-19 vaccine.

India-based pharmaceutical company Zydus has secured approval from the Mexican regulatory agency, COFEPRIS, to conduct a Phase II clinical trial of Desidustat as a potential Covid-19 treatment. Mexican CRO Avant Santé Research Center will be responsible for the drug’s clinical and regulatory development in Covid-19 in Mexico.